| 发明名称 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | ||
| 摘要 | The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided. | ||
| 申请公布号 | US9592288(B2) | 申请公布日期 | 2017.03.14 |
| 申请号 | US201213985342 | 申请日期 | 2012.02.17 |
| 申请人 | The Scripps Research Institute;IRM LLC | 发明人 | Schultz Peter;Lairson Luke;Deshmukh Vishal;Lyssiotis Costas |
| 分类号 | A61K31/5415;A61K31/135;A61K31/137;A61K31/138;A61K31/40;A61K31/439;A61K39/395;A61K38/21 | 主分类号 | A61K31/5415 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method of enhancing a therapeutic effect of an immunomodulatory agent that is effective in treating multiple sclerosis, the method comprising: administering to a human subject having multiple sclerosis the immunomodulatory agent and a muscarinic receptor antagonist; thereby enhancing the therapeutic effect of the immunomodulatory agent in treatment of multiple sclerosis. | ||
| 地址 | La Jolla CA US | ||